Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-03-19 Sale | 2024-03-21 4:41 pm | CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel | 5,268 | $2.0855 | $10,986 | 117,728 (Direct) | View |
| 2024-03-19 Sale | 2024-03-21 4:40 pm | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 20,223 | $2.0855 | $42,175 | 617,639 (Indirect Direct) | View |
| 2024-03-19 Sale | 2024-03-21 4:38 pm | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 2,971 | $2.0855 | $6,196 | 85,686 (Direct) | View |
| 2024-03-19 Sale | 2024-03-21 4:37 pm | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 12,795 | $2.0855 | $26,684 | 168,579 (Direct) | View |
| 2024-03-19 Sale | 2024-03-21 4:36 pm | CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer | 6,562 | $2.0855 | $13,685 | 117,740 (Indirect Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:16 pm | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 13,551 | $1.3807 | $18,710 | 547,862 (Indirect Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:14 pm | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 4,077 | $1.3805 | $5,628 | 155,124 (Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:12 pm | CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer | 4,077 | $1.3805 | $5,628 | 94,302 (Indirect Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:11 pm | CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel | 4,077 | $1.3807 | $5,629 | 97,996 (Direct) | View |
| 2023-12-20 Sale | 2023-12-22 4:10 pm | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 1,990 | $1.3806 | $2,747 | 48,657 (Direct) | View |
| 2023-09-22 Sale | 2023-09-22 7:16 pm | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 4,119 | $1.3003 | $5,356 | 147,951 (Direct) | View |
| 2023-09-22 Sale | 2023-09-22 7:15 pm | CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer | 4,119 | $1.3003 | $5,356 | 84,059 (Indirect Direct) | View |
| 2023-09-22 Sale | 2023-09-22 7:13 pm | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 14,601 | $1.3004 | $18,987 | 523,913 (Indirect Direct) | View |
| 2023-09-22 Sale | 2023-09-22 7:12 pm | CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel | 5,486 | $1.3006 | $7,135 | 80,609 (Direct) | View |
| 2023-03-29 Purchase | 2023-03-31 7:56 pm | CytomX Therapeutics Inc. | CTMX | Jones Elaine V Director | 5,000 | $1.55 | $7,750 | 5,142 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-26 Exercise | 2024-03-28 7:12 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 109,768 | $1.5749 | 727,407 (Direct) | View |
| 2024-03-26 Exercise | 2024-03-28 7:12 pm | N/A 2025-02-08 | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 109,768 | $0 | 727,407 (Direct) | View |
| 2024-03-20 Option Award | 2024-03-22 4:27 pm | N/A 2034-03-19 | CytomX Therapeutics Inc. | CTMX | Su Zhen Director | 76,000 | $0 | 76,000 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-19 8:44 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 770,000 | $0 | 1,317,862 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-19 8:43 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel | 200,000 | $0 | 297,996 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-19 8:41 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 269,000 | $0 | 317,657 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-19 8:40 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer | 245,000 | $0 | 339,302 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-19 8:38 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 223,750 | $0 | 378,874 (Direct) | View |
| 2024-01-18 Option Award | 2024-01-19 8:37 pm | N/A 2034-01-17 | CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer | 223,750 | $0 | 223,750 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:58 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting | 6,875 | $0 | 57,522 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:57 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 37,500 | $0 | 598,913 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:56 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer | 11,250 | $0 | 109,629 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:55 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel | 11,250 | $0 | 113,323 (Direct) | View |
| 2023-12-17 Exercise | 2023-12-19 7:54 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 11,250 | $0 | 170,451 (Direct) | View |
| 2023-09-20 Option Award | 2023-09-22 7:16 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 11,250 | $0 | 147,951 (Direct) | View |
| 2023-09-20 Option Award | 2023-09-22 7:15 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer | 11,250 | $0 | 84,059 (Direct) | View |
| 2023-09-20 Option Award | 2023-09-22 7:13 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 40,000 | $0 | 523,913 (Direct) | View |
| 2023-09-20 Option Award | 2023-09-22 7:12 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel | 15,000 | $0 | 80,609 (Direct) | View |
| 2023-07-19 Option Award | 2023-07-20 5:18 pm | N/A 2033-07-18 | CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer | 375,000 | $0 | 375,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 5:54 pm | N/A 2033-06-13 | CytomX Therapeutics Inc. | CTMX | Meyers James R Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 5:52 pm | N/A 2033-06-13 | CytomX Therapeutics Inc. | CTMX | Mohindru Mani Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 5:51 pm | N/A 2033-06-13 | CytomX Therapeutics Inc. | CTMX | Young Matthew P. Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 5:50 pm | N/A 2033-06-13 | CytomX Therapeutics Inc. | CTMX | Ashworth Alan Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 5:49 pm | N/A 2033-06-13 | CytomX Therapeutics Inc. | CTMX | Gilbert Halley E Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-06-14 Option Award | 2023-06-16 5:49 pm | N/A 2033-06-13 | CytomX Therapeutics Inc. | CTMX | Jones Elaine V Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-05-19 Exercise | 2023-05-23 4:52 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 16,535 | $1.5749 | 618,050 (Direct) | View |
| 2023-05-19 Exercise | 2023-05-23 4:52 pm | N/A 2025-02-08 | CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO | 16,535 | $0 | 618,050 (Direct) | View |
| 2023-03-22 Option Award | 2023-03-29 7:54 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 60,000 | $0 | 140,820 (Direct) | View |
Ownership | 2023-03-29 7:50 pm | N/A N/A | CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer | 0 | $0 | 881,310 (Direct) | View |